#Kodi 18.2 leia builds android skin
#Kodi 18.2 leia builds android trial
#Kodi 18.2 leia builds android free

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. For more information, please visit For information on clinical trials please visit Note Regarding Forward-Looking Statements In addition to these programs, miRagen is developing a pipeline of preclinical product candidates.

MRG-110, an inhibitor of miR-92, is miRagenвЂ™s product candidate for the treatment of heart failure and other ischemic disease. miRagenвЂ™s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. miRagenвЂ™s clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of miR-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has not set a timetable for completion of this process and does not intend to comment further on this process unless or until the Board of Directors has approved a definitive agreement. There can be no assurance that this process will result in any such transaction. Potential strategic alternatives may include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transactions. In addition, as recently announced, the Board of Directors continues to evaluate strategic alternatives for the Company. вЂњOur research and development strategy remains focused on the advancement of our lead program MRG-229 for Idiopathic Pulmonary Fibrosis (IPF).вЂќ Lee Rauch, President and Chief Executive Officer.

вЂњWe have completed this preliminary evaluation and will continue to analyze the final topline data and other secondary SOLAR data as we seek a partner for cobomarsen,вЂќ stated Ms. The downsized SOLAR study is not statistically powered for superiority or equivalence.

#Kodi 18.2 leia builds android trial

In December 2019, miRagen announced it would halt enrollment in the SOLAR trial well short of the intended 126 CTCL patients in order to reduce the time and resource expenditure to evaluate the drugвЂ™s potential. The SOLAR study was designed to evaluate the safety and efficacy of cobomarsen given by intravenous infusion in an active control comparison trial for patients with the mycosis fungoides subtype of CTCL. In addition, cobomarsen was well tolerated, with no patient discontinuations due to cobomarsen-related adverse events.

#Kodi 18.2 leia builds android free

Progression free survival (PFS), a secondary endpoint for the study, indicates a treatment effect in favor of cobomarsen.

#Kodi 18.2 leia builds android skin

Based on investigator assessments, these preliminary data in 37 patients suggest that cobomarsen lacks a compelling result for the study's primary endpoint, objective skin response of at least four months duration (ORR4) relative to the vorinostat control arm. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has conducted an internal review of preliminary topline data from its Phase 2 SOLAR clinical trial of cobomarsen in patients with Cutaneous T-Cell Lymphoma (CTCL). 05, 2020 (GLOBE NEWSWIRE) - miRagen Therapeutics, Inc. MiRagen decides to discontinue further internal development of cobomarsenД«OULDER, Colo., Oct.